Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Vista sencilla de ítem
dc.contributor.authorRuiz-Patinõ, Alejandro
dc.contributor.authorArrieta, Oscar
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorMartín, Claudio Marcelo
dc.contributor.authorRaez, Luis Estuardo
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorBarron, Feliciano
dc.contributor.authorRicaurte, Luisa María
dc.contributor.authorBravo-Garzón, María A.
dc.contributor.authorMas, Luis A.
dc.contributor.authorCorrales, Luis
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorLupinacci, Lorena
dc.contributor.authorPerazzo, Florencia
dc.contributor.authorBas, Carlos Arturo
dc.contributor.authorCarranza, Omar E.
dc.contributor.authorPuparelli, Carmen
dc.contributor.authorRizzo, Miguel M
dc.contributor.authorRuiz, Rossana
dc.contributor.authorRolfo, Christian
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez, July F.
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorCarranza, Hernán
dc.contributor.authorOtero, Jorge Miguel
dc.contributor.authorPino, Luis Eduardo
dc.contributor.authorOrtíz, Carlos
dc.contributor.authorLaguado, Paola
dc.contributor.authorRosell, Rafael Costa
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.date.accessioned2020-03-09T15:30:12Z
dc.date.available2020-03-09T15:30:12Z
dc.date.issued2020
dc.description.abstractenglishBackground: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1111/1759-7714.13272
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1759-7706
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2022
dc.language.isoeng
dc.publisherWiley-Blackwellspa
dc.publisher.journalThoracic Cancerspa
dc.relation.ispartofseriesThoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272
dc.rightsAttribution 4.0 International*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf304
dc.rights.creativecommons2020
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.decsEstadificación de neoplasiasspa
dc.subject.decsSistema nervioso centralspa
dc.subject.decsEstudios de cohortesspa
dc.subject.keywordsAdultspa
dc.subject.keywordsImmunotherapyspa
dc.subject.keywordsLung neoplasmsspa
dc.titleImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)spa
dc.title.translatedImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Ruiz-Patinõ, Alejandro_2020.pdf
Tamaño:
722.2 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos